Avatrombopag

From Wikipedia, the free encyclopedia

Avatrombopag
Avatrombopag.svg
Clinical data
Pronunciationa" va trom' boe pag
Trade namesDoptelet
AHFS/Drugs.comMonograph
MedlinePlusa618032
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
  • 1-[3-Chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H34Cl2N6O3S2
Molar mass649.65 g·mol−1
3D model (JSmol)
  • C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl
  • InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38) checkY
  • Key:OFZJKCQENFPZBH-UHFFFAOYSA-N
 ☒NcheckY (what is this?)

Avatrombopag, sold under the brand name Doptelet, is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure.[1][2] It was approved for medical use in the United States in 2018,[3][4] and in the European Union in 2019.[5]

It acts as a thrombopoietin receptor agonist.[6]

References[edit]

  1. ^ Abdela J (2019). "Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag". Clinical Medicine Insights. Blood Disorders. 12: 1179545X19875105. doi:10.1177/1179545X19875105. PMC 6804364. PMID 31673229.
  2. ^ Markham A (November 2021). "Avatrombopag: A Review in Thrombocytopenia". Drugs. 81 (16): 1905–1913. doi:10.1007/s40265-021-01613-y. PMC 8610948. PMID 34709601.
  3. ^ "FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure". U.S. Food and Drug Administration (FDA) (Press release). 21 May 2018. Retrieved 2 May 2020.
  4. ^ "Drug Approval Package: Doptelet (avatrombopag)". U.S. Food and Drug Administration (FDA). 28 June 2018. Retrieved 2 May 2020.
  5. ^ "Doptelet EPAR". European Medicines Agency (EMA). 24 April 2019. Retrieved 2 May 2020.
  6. ^ Kuter DJ (November 2021). "The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag". Blood Reviews. 53: 100909. doi:10.1016/j.blre.2021.100909. PMID 34815110. S2CID 244285488.

External links[edit]

  • "Avatrombopag". Drug Information Portal. U.S. National Library of Medicine.